01906nas a2200241   4500000000100000008004100001260000900042653002900051653001100080653002300091653002500114653002200139653001400161100002300175700001600198700001200214700001400226245008200240300001000322490001400332520130400346022001401650       1989                            d  c198910aClinical Trials as Topic10aHumans10aLeprostatic Agents10aLeprosy, lepromatous10aRosette Formation10aSerotonin1 aMester de Parajd M1 aAmbrose E J1 aTayeb N1 aAntia N H00a[Desoxyfructo-serotonin: its therapeutic effect in the treatment of leprosy].  a200-20 v7 Suppl 13 a<p>Desoxyfructo-serotonin (DFS) has shown good results in clinical trials of LL patients. After clinical trials in Bamako (Mali) reported in three articles, clinical trials began in India, at Bombay. Acute toxicity tests done in Paris and chronic toxicity tests done in India had shown absence of side effects. This was also confirmed after pre-clinical pharmacology. In vitro tests show that DFS enhances cellular immune response. Receptors for anti-erythrocyte antibody on LL macrophages are demonstrated by erythrocyte rosetting. Infection with M. leprae markedly reduces rosetting. But in the presence of DFS this reduction in rosetting is not observed. Patient's peripheral blood lymphocytes, sensitised with leprosy antigen, show a low level of rosetting with patients' macrophages. DFS greatly enhances the lymphocyte-macrophage interaction. DFS has an important anti-stress activity. Gastric ulcer induced in rats by restraint were reduced by 40% (Mester et al.) and 50% (Das Neves). DFS increased the uptake of serotonin by LL patients platelets. HPLC studies were done to see the level of DFS in the plasma, in the serum and in the urine of LL patients and controls. We are synthetising new lyposoluble derivatives in order to make easier the penetration of DFS and a long time effect.</p>  a0001-5938